Bio-Techne Corporation TECH

Revenue Intelligence Report • 50 quarters of SEC filing data • Updated 2026-03-06

The company's revenue growth is primarily driven by effective management of selling, general, and administrative (SG&A) expenses, with a 1% increase in SG&A resulting in a 0.53% boost in revenue, highlighting a strong return on investment in this area. With a solid model accuracy of 3.2% MAPE and a holdout test indicating a minor prediction error, the company is positioned well for the future. For the fiscal year, the forecasted revenue of $1,288 million represents a 7.8% year-over-year increase, reflecting a positive outlook for continued growth. Investors can expect that strategic spending will further enhance revenue performance in the coming quarters.

Next FY Revenue

$1288.50M

+7.8% YoY

SG&A Elasticity

0.53x

Model Accuracy

3.2% MAPE

Holdout validation: The model predicted $301M vs the actual $296M — an error of 1.6%.

Note: Bio-Techne Corporation does not report R&D expenses separately. This analysis uses SG&A spending only.

Revenue Forecast

Quarterly Detail

Quarter	Model Forecast	Actual	95% Range	YoY Growth	Status
Q4 2025	$301M	$296M	$278M – $325M	+3.9%	✓ In range
Q2 2026	$316M		$282M – $353M	+6.2%
Q3 2026	$317M		$276M – $363M	+0.2%
Q4 2026	$321M		$275M – $376M	+12.1%
Q1 2027	$335M		$281M – $399M	+13.2%

How Spending Drives Revenue

Reading this chart: Each line shows the cumulative elasticity — how a 1% increase in spending translates to revenue growth over subsequent quarters. The effect builds over 4-5 quarters as investments compound.

Want this analysis for your portfolio?

I build custom revenue intelligence reports for investors and companies using SEC filing data, econometric modeling, and AI-powered insights.

Get in Touch